Efficacy and Safety of a Purified Standardised Wasp Venom Preparation
Phase 3
Completed
- Conditions
- Allergy
- Registration Number
- NCT00263926
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Brief Summary
The trial is performed to assess efficacy and safety of a purified standardised wasp venom preparation in wasp venom allergy
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- History of wasp venom allergy,
- Positive RAST to wasp venom,
- Positive skin prick test to wasp venom
Exclusion Criteria
- Serious chronic diseases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the purified wasp venom preparation's efficacy in allergy immunotherapy?
How does the purified standardised wasp venom compare to conventional aqueous venom in desensitization outcomes?
Which biomarkers correlate with successful immunotherapy outcomes in wasp venom allergy patients?
What are the long-term safety profiles of purified versus conventional wasp venom preparations in clinical practice?
Are there combination approaches or competitor drugs that enhance wasp venom allergy treatment efficacy?
Trial Locations
- Locations (1)
Allergopharma GmbH & Co. KG
🇩🇪Reinbek, Germany
Allergopharma GmbH & Co. KG🇩🇪Reinbek, Germany